Skip to main content

Market Overview

PTC Therapeutics-Roche's Evrysdi Approved In Europe For Muscular Atrophy

  • The European Commission (EC) has granted marketing authorization to PTC Therapeutics Inc's (NASDAQ: PTCT) Evrysdi (risdiplam) for the treatment of spinal muscular atrophy (SMA) in patients two months and older.
  • Evrysdi will be for SMA Type 1, Type 2, or Type 3 patients with one to four SMN2 copies.
  • The EC approval is based on two studies - Efficacy results from the FIREFISH study in infants aged 2 to 7 months with symptomatic Type 1 SMA and the SUNFISH study in children and young adults with Type 2 or 3 SMA.
  • Evrysdi is commercialized in the U.S. by Genentech, a Roche Holdings AG member (OTCMKTS: RHHBY).
  • Roche leads the clinical development of Evrysdi as part of a collaboration with the SMA Foundation and PTC Therapeutics.
  • Price Action: PTCT shares closed 2.3% lower at $48.06 on Monday.

Related Articles (RHHBY + RHHBF)

View Comments and Join the Discussion!

Posted-In: European Commission Spinal Muscular AtrophyBiotech News Health Care FDA General

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at